Ozobax - (5 mg/5 mL ; Oral Solution)

Generic Name	Baclofen	Innovator	Metacel Pharma
Dosage	5 mg/5 mL ; Oral Solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	Less Than 5	Generic Launches	None
Indication	OZOBAX is a gamma-aminobutyric acid (GABA-ergic) agonist indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. OZOBAX may also be of some value in patients with spinal cord injuries and other spinal cord diseases.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******* ********	*** \ ***	***** **, ****	*** ** **	********	*** ****** *******

Chronology Of Events